GlassScriptPhysician profile
Jacob Erik Gardner
NPI 1013500461
$1,229.97
in general payments reported to CMS, 2019-2025
25 companies · $80.47 in 2025
The $80.47 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $459 · 2022: $118 · 2024: $573 · 2025: $80.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $653.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $227.53 | 2021-2024 | |
| Alkermes, INC. | $99.98 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $81.18 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.45 | 2021-2024 | Hyqvia |
| Pfizer INC. | $76.26 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.53 | 2021 | |
| Neurelis, INC. | $68.20 | 2024-2025 | Valtoco |
| Lundbeck LLC | $53.45 | 2021-2024 | Vyepti |
| Averitas Pharma INC. | $52.58 | 2024-2025 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $40.06 | 2022-2024 | Rexulti |
| Avanir Pharmaceuticals, INC. | $39.98 | 2021 | |
| Celgene Corporation | $39.50 | 2024 | Zeposia |
| Harmony Biosciences LLC | $33.10 | 2024 | |
| Argenx US, INC. | $32.83 | 2024 | Vyvgart Hytrulo |
| Ucb, INC. | $28.25 | 2024 | Briviact |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $24.43 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $23.61 | 2024 | Wainua |
| Amneal Pharmaceuticals LLC | $23.54 | 2024 | Ongentys |
| Acadia Pharmaceuticals INC | $22.67 | 2024 | Nuplazid |
| Lilly USA, LLC | $22.51 | 2024 | Kisunla, Amyvid |
| Neurocrine Biosciences, INC. | $21.87 | 2021 | |
| Sun Pharmaceutical Industries INC. | $19.42 | 2021 | |
| Amgen INC. | $19.02 | 2024 | Uplizna |
| Biogen, INC. | $17.86 | 2024 | Tysabri |
| Novartis Pharmaceuticals Corporation | $15.16 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.